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Instead of focusing on the pathogen, in a paradigm shift, Zaas et al. (2009) identified host gene profiles as
a strategy for diagnosis of respiratory infections. Application of host gene profiles offers tremendous possi-
bilities for identification of diagnostic signatures, markers of disease severity, and eventually, prognostic
indicators in the clinical setting.Acute respiratory infections are respon-
sible for a large number of outpatient visits
and hospitalizations worldwide. Tradition-
ally, most of its morbidity and mortality
has been attributed to bacterial infections,
but increasing evidence indicates that
viral respiratory infections play a substan-
tial role as well (Hall et al., 2009). In the
current clinical practice setting, establish-
ing a precise etiologic diagnosis or even
discriminating viral from bacterial respira-
tory infections remains a challenge. This is
true when evaluating both outpatients in
the clinic or the emergency room as well
as hospitalized individuals. Unfortunately,
the difficulties in differentiating viral from
bacterial infections and the pressure to
achieve a rapid resolution of symptoms
commonly lead medical practitioners to
take an overcautious approach and to
unnecessarily treat many patients with
antibiotics (Wachter et al., 2008). Obvi-
ously, this is a flawed approach that,
besides driving up health care costs, facil-
itates the development of antimicrobial
resistance. Improvement of our diag-
nostic capabilities is warranted. In recent
years, the introduction of molecular PCR-
based assays has dramatically changed
our ability to accurately diagnose viral
respiratory infections caused by both
well-known and recently discovered
viruses (Mahony, 2008). Despite these
advances in the diagnosis of viral infec-
tions, molecular assays have been less
successful for the diagnosis of bacterial
respiratory infections, especially those
caused by pneumococcus and other
invasive bacteria (Anevlavis et al., 2009;
Nolte, 2008). To complicate matters
further, in many instances, the detection
of a specific microbe in clinical samplesis not sufficient to make a specific diag-
nosis. Hence, there is an urgent need for
new methodologies to improve the diag-
nosis of acute respiratory infections.
In a study published in this issue of Cell
Host & Microbe, Zaas et al. (Zaas et al.,
2009) provide a first glimpse for such
alternative approaches. In a paradigm
shift, instead of focusing on the pathogen,
they identified host gene response signa-
tures as a novel strategy for diagnosis
of respiratory infections. They analyzed
blood gene expression profiles in healthy
volunteers experimentally infected with
rhinovirus (HRV), respiratory syncytial
virus (RSV), and influenza A virus and,
using a factor type of analysis, identified
an ‘‘acute viral respiratory signature’’
that clearly distinguished symptomatic
infected individuals from asymptomatic
uninfected volunteers. The ‘‘acute viral
signature’’ contained genes such as
RSAD2, IFI44L, and LAMP3 that were
shared by all three viral infections. They
also identified genes that were more
specific for each viral infection, e.g.,
OAS2, CXCL10, and SOCS1 for HRV;
FCRGR1A, GBP1, and LAP3 for RSV;
and TNFAIP1, SEPT4, and IFI27 for influ-
enza, providing further evidence of the
potential value of this approach to define
diagnostic signatures that are common
for a group of pathogens and those that
are pathogen-specific. To validate their
findings, they applied the newly identified
viral signature to an independent, previ-
ously published data set of patients with
community-acquired respiratory infec-
tions (Ramilo et al., 2007). Despite the
technical challenges involved in such
analysis, the viral signature classified
patients with influenza A from healthyCell Host & Microbe 6, Sage-matched controls with 100% accu-
racy. In the same data set, the viral signa-
ture distinguished viral from bacterial
respiratory infections with 93% precision.
These observations confirm the tre-
mendous value of gene signatures for
clinical application in infectious diseases.
The data clearly support the hypothesis
that different pathogens elicit a distinct
host immune response and that the
information is readily available in blood
immune cells (Figure 1).
It is remarkable that blood signatures
can achieve such accuracy for diagnosis
of respiratory viral pathogens that are
thought to be confined to the respiratory
tract. From the practical perspective, in
most clinical situations, obtaining a blood
sample is more feasible than obtaining
infected tissue. The application of gene
signatures to accurately classify patients
according to the infectious etiologic agent
has shown to be noteworthy; however, the
comprehensive assessment of the host
response also provides an opportunity to
use them in a broader clinical context. A
major advantage of this approach is the
ability to correlate clinical markers of
disease severity with changes in host
gene expression by developing a genomic
severity score that can help classifying
patients according to clinical conditions
(Chaussabel et al., 2008). Developing an
objective score of disease severity will
be extremely helpful to monitor disease
status and response to therapy and even-
tually predict clinical outcomes. The tools
necessary to implement this approach in
the clinical setting are currently available.
In fact, we have now at our disposal
molecular methods that have shown their
reproducibility across different data sets,eptember 17, 2009 ª2009 Elsevier Inc. 199
Cell Host & Microbe
PreviewsFigure 1. Host Gene Signatures: A New Approach for Diagnosis of Infectious Diseases
(A) Different classes of pathogens trigger specific pattern-recognition receptors (PRRs) differentially
expressed on immune cells and elicit distinct immune responses.
(B) Using microarray technology, we can measure the differences in gene expression patterns present in
blood immune cells as induced by various types of infectious agents.as well as robust new statistical analytical
tools that allow comprehensive data
mining and reduction of the dimensionality
of the complex gene expression array data
sets (Chaussabel et al., 2008; Zaas et al.,
2009). Now, the challenge is designing
relevant clinical studies to identify and
validate the diagnostic and prognostic
signatures induced by relevant patho-
gens. Focusing on respiratory infections,
studies should combine state of the art
molecular and traditional microbiologic
methods with host gene signatures.
Combining the detection of the pathogen
with a comprehensive assessment of
the host immune response will provide
a broad new understanding of the correla-
tions between specific etiologic agents,
the corresponding host response, and
the clinical manifestations of the disease.
This combined approach will help in
developing a large data bank of diagnostic
signatures and biomarkers of disease
severity. It will also improve our under-
standing of the disease pathogenesis
and will help to determine the role of
a pathogen detected in a clinical sample,200 Cell Host & Microbe 6, September 17, 20whether it implies that the microbe is
causing the disease or that it simply
reflects colonization and/or asymptom-
atic shedding. In addition, these assays
will be extremely valuable to study the sig-
nificance of dual or triple viral coinfections
as well as viral-bacterial coinfections.
Infectious diseases offer an ideal
setting to bring these methodologies
from the bench to a practical application
in the clinical setting. The host gene-
based approaches are not substitutes
for pathogen-based diagnosis, but
instead provide different and comple-
mentary information. Many different areas
of infectious diseases can benefit tremen-
dously from the application of diagnostic
strategies that target both the pathogen
and the host immune response. Evalua-
tion of patients with acute febrile illnesses,
patients with suspected sepsis and men-
ingitis or meningoencephalitis, among
others, can be revolutionized by these
methods. This approach can become
extremely useful to evaluate patients
with febrile illnesses of unclear etiology;
to develop novel diagnostic signatures09 ª2009 Elsevier Inc.for known conditions of uncertain
etiology, such as Kawasaki Disease
(Popper et al., 2009); and to differentiate
infectious diseases from autoimmune
conditions that can have identical clinical
presentation, such as Systemic Onset
Juvenile Idiopathic Arthritis (Allantaz
et al., 2007). Indeed, the clinical applica-
tion of microarray technologies to study
autoimmune diseases has uncovered
mechanisms of disease pathogenesis as
well as identification of novel biomarkers
that helped in establishing the diagnosis
and monitoring disease activity. This is
a model to follow in other areas of clinical
medicine.
In summary, the stage is ready for
a broad clinical application of gene
expression assays in infectious diseases.
It is up to us, the investigators, to design
appropriate clinical studies to exploit the
full potential of these technologies and,
more important, to improve the outcomes
of our patients.
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